	Application No.	Applicant(s)
Notice of Allowability	10/783,451 Examiner	DIB ET AL.
,	Lamino	7. Since
	Phyllis G. Spivack	1614
The MAILING DATE of this communication appearable All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in to or other appropriate communing GHTS. This application is sulfi-	his application. If not included ication will be mailed in due course. THIS
1. This communication is responsive to <u>July 27, 2005</u> .		
2. The allowed claim(s) is/are <u>1-20</u> .		
3. The drawings filed on are accepted by the Examiner	г.	
 4. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	been received. been received in Application	No. <u>10/164,771</u> .
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a IENT of this application.	reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
6. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the	on's Patent Drawing Review (s Amendment / Comment or in 84(c)) should be written on the	the Office action of drawings in the front (not the back) of
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATEF FOR THE DEPOSIT OF BIOL	RIAL must be submitted. Note the OGICAL MATERIAL.
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Sun Paper No./M 7. ☐ Examiner's A	ail Date mendment/Comment satement of Reasons for Allowance PHYLLIS SPIVACK
		PRIMARY EXAMINER

Application/Control Number: 10/783,451

Art Unit: 1614

The following is an Examiner's statement of reasons for allowance:

Applicants' Amendment filed July 27, 2005 is acknowledged. Claim 21 is canceled. Claims 1-20 remain under consideration.

In the last Office Action claim 10 was rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 8 of U.S. Patent 6,720,318.

Following the submission of a Terminal Disclaimer, this rejection of record is withdrawn.

Subsequent to the cancellation of claim 21, which was asserted to be a substantial duplicate of claim 16, the objection of record under 37 CFR 1.75, is moot.

The closest prior art is deemed Broekkamp et al., U.S. Patent 6,150,353. Broekkamp requires mirtazapine in a combination with an antipsychotic agent of which cyamemazine, sertindole, quetiapine and ziprasidone are options for use in the treatment of schizophrenia and schizophreniaform disorders. The present claims require cyamemazine in combination with one of the group consisting of sertindole, quetiapine and ziprasidone. Broekkamp does not render the instant invention obvious in the absence of additional information.

Accordingly, claims 1-20 are allowed in view of the contemporary knowledge of the art.

Any comments considered necessary by Applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Art Unit: 1614

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached Monday to Friday from 10:30 AM to 7PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Chris Low, can be reached at 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Phyllis G. Spivack Primary Examiner Art Unit 1614

PHYLLIS SPIVACK PRIMARY EXAMINER

August 7, 2005